Comparative Pharmacology
Head-to-head clinical analysis: FLUTEX versus PALSONIFY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTEX versus PALSONIFY.
FLUTEX vs PALSONIFY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flutamide is a nonsteroidal antiandrogen that competitively inhibits the binding of dihydrotestosterone (DHT) to androgen receptors in target tissues, thereby blocking the androgenic effects.
Selective serotonin reuptake inhibitor (SSRI) that enhances serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby increasing extracellular serotonin levels in the brain.
50 mg orally once daily
70 mg/m2 IV every 3 weeks. Infusion over 60 minutes.
None Documented
None Documented
Terminal elimination half-life: 24–36 hours, permitting once-daily dosing in chronic therapy
Terminal half-life 12 hours (range 10–14 h) in healthy adults; prolonged to 24–30 h in severe renal impairment (CrCl <30 mL/min)
Renal: ~70% (50% unchanged, 20% as metabolites); Biliary/fecal: ~30%
Renal: 65% unchanged; biliary/fecal: 30% as metabolites; 5% other
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid